Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M.sub.4 (mAChR M.sub.4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

The present invention relates to methods and compositions for the treatment of psychiatric disorders such as treatment-resistant depression (TRD) with KCNQ (also known as Kv7) channel openers. Also disclosed is a method of inducing or enhancing resilience in a patient by administration of a KCNQ channel opener, such as ezogabine.

The present invention relates to methods and compositions for the treatment of psychiatric disorders such as treatment-resistant depression (TRD) with KCNQ (also known as Kv7) channel openers. Also disclosed is a method of inducing or enhancing resilience in a patient by administration of a KCNQ channel opener, such as ezogabine.

The present invention relates to a clostridial neurotoxin for use in treating post-operative surgical pain in a patient, said method comprising administering to a patient a clostridial neurotoxin more than 5 days prior to surgery and wherein the clostridial neurotoxin is administered: i) intradermally; or ii) intrathecally.

Also provided are corresponding methods of treatment and administration dosages of a clostridial neurotoxin.

The present invention relates to a clostridial neurotoxin for use in treating post-operative surgical pain in a patient, said method comprising administering to a patient a clostridial neurotoxin more than 5 days prior to surgery and wherein the clostridial neurotoxin is administered: i) intradermally; or ii) intrathecally.

Also provided are corresponding methods of treatment and administration dosages of a clostridial neurotoxin.

Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.

Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

The invention relates to pharmaceutical compositions comprising Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabigerol (CBG) and a terpene component, and their use in the treatment of chronic pain. The invention also relates to methods for treating chronic pain, especially chronic pain in athletes.